Taktile Secures $110M in Goldman Sachs-led Series C to Power AI Transformation in Financial Institutions
24.6.2026 16:30:00 EEST | Business Wire | Press release
Taktile, the leader in AI transformation for financial institutions, today announced its $110 million Series C fundraise. Growth Equity at Goldman Sachs Alternatives led the round, with participation from Balderton Capital, Index Ventures, Tiger Global, Y Combinator, and Dig Ventures.
Taktile Fast Facts
- Taktile enables banks and insurers to transform into AI-native organizations that are increasingly powered by autonomous agents.
- Demand for Taktile accelerated in 2025, as AI models became capable of automating high-stakes decisions that previously required hours of manual work—from underwriting business loans and assessing claims to catching financial crime.
- Customers automate and optimize decisions with Taktile by combining its financial services expertise and product built for sector-specific AI use cases. One of the world’s largest insurers is running multiple use cases on Taktile, with projected cost efficiencies of over $90M in claims processing alone.
- Taktile’s team has a proven track record of bringing AI agents into production within complex enterprises. Trusted by customers including Mercury, Monzo, Faire, and Pleo, the company has powered outcomes such as 95% automation in B2B underwriting and 75% fewer anti-money laundering (AML) false positives.
Taktile’s most recent breakthrough came in December 2025, when the company's applied AI research institute, Taktile Labs, found that frontier models had crossed a critical threshold. AI could now handle the kind of high-stakes decisions that financial institutions had long reserved for human experts: Moody's reports that financial institutions are spending an average of $72.9 million annually on KYC and AML operations alone.
For the first time, AI is capable of reliably automating much of this repetitive, time-consuming work. But banks and insurers still need a way to operationalize autonomous agents reliably and at scale, so they can empower their workforce with this vital new tool. While generalist AI labs provide raw building blocks to engineers, Taktile gives institutions a way to operate AI-driven decisions within a system that business owners—from heads of credit to fraud officers—can understand and control.
"General purpose AI tooling is fine for simple automations, but it isn’t sufficient for operating mission-critical financial decisions where errors can cost millions," said Taktile CEO and Co-Founder Maik Taro Wehmeyer. "Today, thousands of employees process these decisions manually. Leaders want to redeploy that capacity to higher-value work, while ensuring every outcome—whether human or AI-driven—remains the best for the business and customers. This is what Taktile enables.”
"Taktile stands out for combining deep technical sophistication with a clear understanding of how regulated financial institutions actually operate. They work with a broad spectrum of financial institutions to build, test and automate complex workflows that meet their specific needs," said Christian Resch, Partner in Growth Equity at Goldman Sachs Alternatives.
"Banks and insurers consistently tell us that Taktile has helped them transform how their teams make decisions with AI—unlocking faster product launches, sharper risk outcomes, and meaningful operational efficiency," added Jade Mandel, Managing Director in Growth Equity at Goldman Sachs Alternatives. "Taktile has built something rare: a team and a product that enables financial institutions to unlock real value from AI where it's most complex—inside high-stakes, regulated decisions. We're excited to partner with Maik, Max, and the Taktile team."
Taktile will use the capital to further enhance its AI solutions for complex banking and insurance use cases, and expand its global footprint across the US, EMEA, and LATAM.
About Taktile
Taktile enables financial institutions to transform into AI-native organizations that are increasingly powered by autonomous agents. With our modular Agentic Decision Platform, customers combine AI agents, rules, relevant context, and human oversight to safely automate and optimize their decisions—approving more customers, reimbursing claims instantly, stopping fraud before it spreads, and financing every business worth funding. Founded in 2020, Taktile powers millions of decisions daily for institutions including Mercury, Monzo, Faire, and Pleo. With offices in New York, Berlin, London, São Paulo, and Iași, the company has raised $184M from Growth Equity at Goldman Sachs Alternatives, Index Ventures, Tiger Global, Balderton Capital, and Y Combinator. Learn more at taktile.com.
About Growth Equity at Goldman Sachs Alternatives
Goldman Sachs (NYSE: GS) is one of the leading investors in alternatives globally, with over $625 billion in assets and more than 30 years of experience. The business invests in the full spectrum of alternatives including private equity, growth equity, venture capital, private credit, real estate, infrastructure, sustainability, and hedge funds. Clients access these solutions through direct strategies, customized partnerships, and open-architecture programs.
The alternative investments platform is part of Goldman Sachs Asset Management, which delivers investment and advisory services across public and private markets for the world’s leading institutions, financial advisors and individuals. Goldman Sachs has approximately $3.7 trillion in assets under supervision globally as of March 31, 2026.
Since 2003, Goldman Sachs Growth Equity has invested over $13 billion in companies led by visionary founders and CEOs. The team focuses on investments in growth stage and technology-driven companies spanning multiple industries, including enterprise technology, financial technology, consumer and healthcare. Follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260624880263/en/
Contacts
Media Contact
Nadia Bovy
nadia.bovy@taktile.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom